Lead Product(s) : Sugemalimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CStone Announces EC Approval of Sugemalimab as First-Line Treatment for NSCLC
Details : Cejemly (sugemalimab) is an anti-PD-L1 monoclonal antibody, which is currently being evaluated for the first-line treatment for non-small cell lung cancer.
Brand Name : Cejemly
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 26, 2024
Lead Product(s) : Sugemalimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugemalimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CStone’s Cejemly® Recommended for NSCLC First-Line Treatment by EMA CHMP
Details : Cejemly (sugemalimab) is an anti-PD-L1 monoclonal antibody, which is currently being evaluated for the first-line treatment for non-small cell lung cancer.
Brand Name : Cejemly
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 01, 2024
Lead Product(s) : Sugemalimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cejemly (sugemalimab) is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody, being investigated against locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma.
Brand Name : Cejemly
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 28, 2023
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cejemly (sugemalimab) is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody, being investigated against metastatic squamous and non-squamous non-small cell lung cancer.
Brand Name : Cejemly
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 23, 2023
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugemalimab,Fluorouracil,Cisplatin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cejemly (sugemalimab) is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody, being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma.
Brand Name : Cejemly
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 03, 2023
Lead Product(s) : Sugemalimab,Fluorouracil,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the final progression-free survival analysis, CS1001 (sugemalimab) showed sustained clinical benefits in patients with unresectable stage III nSCLC whose disease had not progressed following concurrent or sequential chemoradiotherapy compared with pla...
Brand Name : Cejemly
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 08, 2022
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The National Medical Products Administration approved Cejemly (sugemalimab) for treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiother...
Brand Name : Cejemly
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 06, 2022
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Approval from China’s NMPA for sugemalimab (Cejemly®), an OmniAb-derived anti-PD-L1 monoclonal antibody, for the first-line treatment of metastatic NSCLC in combination with chemotherapy is based on the Phase 3 study.
Brand Name : Cejemly
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 22, 2021
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
China NMPA Accepts CStone’s NDA for Sugemalimab to Treat Unresectable Stage III NSCLC
Details : Sugemalimab is the world’s first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemo...
Brand Name : CS1001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 02, 2021
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : CStone Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GEMSTONE-301 study investigating sugemalimab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC without disease progression after either concurrent or sequential chemoradiotherapy.
Brand Name : CS1001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 28, 2021
Lead Product(s) : Sugemalimab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : CStone Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?